Compare RVYL & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | XAIR |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.5M |
| IPO Year | N/A | N/A |
| Metric | RVYL | XAIR |
|---|---|---|
| Price | $6.31 | $1.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 838.4K | ★ 22.5M |
| Earning Date | 11-14-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,858,000.00 | $5,802,000.00 |
| Revenue This Year | N/A | $127.85 |
| Revenue Next Year | $297.49 | $179.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 29.50 | ★ 147.74 |
| 52 Week Low | $4.50 | $0.67 |
| 52 Week High | $81.55 | $10.40 |
| Indicator | RVYL | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 46.38 |
| Support Level | $5.30 | $1.43 |
| Resistance Level | $7.68 | $2.26 |
| Average True Range (ATR) | 1.03 | 0.33 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 39.58 | 20.53 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.